Compare Adaptive Biotechnologies Corp (ADPT) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs NEOS S&P 500 High Income ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.06 (market cap $3.33B), while NEOS S&P 500 High Income ETF trades at $53.08. Which is the better fit depends on your goals.
| ADPT | SPYI | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $22.37 | $54.07 |
52-Week Low | $10.24 | $47.98 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
SPYI trades at $53.45, up 0.74% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF has surpassed $10 billion in assets under management, driven by strong demand for its covered-call strategy that delivers an 11.86% yield. Recent dividends of $0.52-$0.54 per share highlight its income focus, though key valuation ratios like P/E and P/B are not applicable for this ETF structure.
Outlook remains positive due to robust investor inflows and competitive yield advantages over peers like JEPI. Risks include high fees impacting long-term returns and potential volatility from its options strategy. The fund's tax-efficient distributions appeal to retirees, but reliance on return of capital requires careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
